PYPD
PolyPid·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
PYPD fundamentals
PolyPid (PYPD) released its earnings on Nov 12, 2025: revenue was 0 (YoY 0.00%), beat estimates; EPS was -0.37 (YoY +69.67%), beat estimates.
Revenue / YoY
0
0.00%
EPS / YoY
-0.37
+69.67%
Report date
Nov 12, 2025
PYPD Earnings Call Summary for Q3,2025
- FDA Milestone Confidence: Pre-NDA meeting in December to secure 2026 submission, with $18.8M cash runway.
- Commercial Momentum: 80% hospital formulary uptake and 60% surgeon utilization rate from market study.
- Financial Strength: Reduced debt to $2.4M, improved net loss to $7.5M, and strategic U.S. manufacturing expansion considerations.
EPS
Revenue
Revenue & Expenses
Key Indicators
PolyPid (PYPD) key financial stats and ratios, covering profitability, financial health, and leverage.
PolyPid (PYPD)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown
PolyPid (PYPD)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown
PolyPid (PYPD)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown
Where does PolyPid (PYPD) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:
Track PolyPid (PYPD) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield
You can ask Aime
What were the key takeaways from PolyPid’s earnings call?What factors drove the changes in PolyPid's revenue and profit?What is PolyPid's latest dividend and current dividend yield?What is PolyPid's gross profit margin?What were the key takeaways from PolyPid's earnings call?What is the revenue and EPS growth rate for PolyPid year over year?What is the market's earnings forecast for PolyPid next quarter?What guidance did PolyPid's management provide for the next earnings period?
